６ ０ ８ 号 認 知 症 新 時 代 へ の 挑 戦 no.608 ク リ ニ シ ア ン ２ ０ １ ２年５月１日発行 年間１ ０回発行 発行 東京都文京区小石川４ ６ １ ０ vol.59 no.608 認知症 クリニシアン 発行人 直江 登 印刷 ひでじま 59巻4 5合併号 通巻608号 認知症新時代への挑戦 認知症新時代への挑戦 鳥取大学医学部 脳神経医科学講座脳神経内科学分野教授 中島健二 ２ 座談会 認知症を抱える本人の視点 ６ 座長 筑波大学 医学医療系臨床医学域精神医学教授 朝田 隆 川崎医科大学 神経内科特任准教授 認知症疾患医療センター副センター長 片山禎夫 こだまクリニック 院長 木之下 徹 独立行政法人国立長寿医療研究センター 第二脳機能診療科医長 武田章敬 オブザーバー 厚生労働省 老健局局長 宮島俊彦 インタビュー 本人からのメッセージ 佐藤雅彦 ２ １ 認知症のパラダイムシフト 認知症の人の生活を知る 認知症の人の生活機能障害 札幌医科大学医学部 リハビリテーション医学講座教授 石合純夫 ２ ６ 帰宅願望ともの盗られ妄想 愛媛大学大学院医学系研究科 脳とこころの医学准教授 谷向 知 ３ １ 脱抑制行動 常同行動 熊本大学医学部附属病院 神経精神科講師 橋本 衛 ３ ７ 易怒性 岩手医科大学医学部 災害医学講座特命教授 高橋 智 ４ ２ 幻覚 妄想 誤認 滋賀県立成人病センター 老年内科副部長 長濱康弘 ４ ８ 本人視点からアリセプト!を再考する! ドネペジル アリセプト は!興奮"させる薬剤か 首都大学東京 大学院人間健康科学研究科教授 繁田雅弘 ５ ６ アリセプト!の投与意義 ナーシングホームデータから言えること 大阪赤十字病院 神経内科副部長 金田大太 ６ ０ ドネペジル塩酸塩の効果をどうみるか ねぎし内科 神経内科クリニック 院長 根岸輝彦 ６ ７ 認知症治療の真のエンドポイントを考える 医療法人社団こだま会 こだまクリニック 臨床心理士 安田朝子 ７ ７ MCI で抗認知症薬を投与すべきか 神戸大学大学院医学研究科 神経内科学分野准教授 古和久朋 ８ ３ これからの認知症で果たすべき役割! アリセプト の登場は患者の受診行動にどのような変化を与えたか 受診行動からの検討 三重大学大学院医学系研究科 認知症医療学講座准教授 佐藤正之ほか ８ ９ 認知症診療１ ０年の変遷と地域連携 三重大学大学院医学系研究科 認知症医療学講座助教 木田博隆ほか ９ ４ 認知症診療でかかりつけ医に期待する役割 岡山大学 脳神経内科教授 阿部康二 ９ ９ 認知症診療でかかりつけ医が果たすべきこと 弓倉医院 院長 弓倉 整 １ ０ ６ 抗認知症薬の服薬継続の意義と薬剤師の役割 愛知学院大学薬学部 臨床薬剤学講座教授 山村恵子 １ １ １ 高齢者にやさしい剤形選択 昭和大学薬学部 薬物療法学講座 薬剤学部門准教授 倉田なおみ １ １ ７ 私の座右銘 第３ ９ ９回 鳥取大学医学部 脳神経医科学講座脳神経内科学分野教授 中島健二 表２ ７ ３ 連載 GP のためのセミナー 先端医学トレンド１２７ 大阪大学産学連携本部 脳神経制御外科学特任教授 齋藤洋一 新連載 住み慣れた地域で誰もがいきいきと暮らせるまちづくり １ ２ ４ 認知症介護研究 研修東京センター 研究部副部長 永田久美子 １ ３ ４ 連載 １/ f 聖路加国際病院 小児科部長 副院長 細谷亮太 表紙 鳥取大学医学部 脳神経医科学講座脳神経内科学分野教授 中島健二先生 CODE CN 1 608
no.608 vol.59 no.608 5945608 CODE CN1608
CLINICIAN 12 NO. 608 2
3 CLINICIAN 12 NO. 608
disease modifying therapy CLINICIAN 12 NO. 608 4
5 CLINICIAN 12 NO. 608
CLINICIAN 12 NO. 608 6
common disease behavioral and psychological symptoms of dementia 7 CLINICIAN 12 NO. 608
CLINICIAN 12 NO. 608 8
9 CLINICIAN 12 NO. 608
CLINICIAN 12 NO. 608 10
11 CLINICIAN 12 NO. 608
Values people Treat people as Individuals Perspective of service user Supportive social psychology CLINICIAN 12 NO. 608 12
13 CLINICIAN 12 NO. 608
cure CLINICIAN 12 NO. 608 14
15 CLINICIAN 12 NO. 608
CLINICIAN 12 NO. 608 16
common disease 17 CLINICIAN 12 NO. 608
CLINICIAN 12 NO. 608 18
19 CLINICIAN 12 NO. 608
CLINICIAN 12 NO. 608 20
21 CLINICIAN 12 NO. 608
CLINICIAN 12 NO. 608 22
23 CLINICIAN 12 NO. 608
CLINICIAN 12 NO. 608 24
25 CLINICIAN 12 NO. 608
CLINICIAN 12 NO. 608 26
27 CLINICIAN 12 NO. 608
limb apraxia Liepmann naturalistic actions CLINICIAN 12 NO. 608 28
29 CLINICIAN 12 NO. 608
Multi-level action test Schwartz, M. F., et al. : Naturalistic action production following right hemisphere stroke. Neuropsychologia, 37, 51-66 (1999) CLINICIAN 12 NO. 608 30
Behavioral and Psychological Symptoms of Dementia 31 CLINICIAN 12 NO. 608
Sundown Syndrome CLINICIAN 12 NO. 608 32
NPINeuropsychiatric Inventory 33 CLINICIAN 12 NO. 608
CLINICIAN 12 NO. 608 34
35 CLINICIAN 12 NO. 608
Ikeda, M., et al. : Delusions of Japanese patients with Alzheimer s disease. Int. J. Geriatr. Psychiatry, 18, 527-532 (2003) Kazui, H., et al. : Impact of emotion memory. Controlled study of the influence of emotionally charged material on declarative memory in Alzheimer s disease. Br. J. Psychiatry, 177, 343-347 (2000) CLINICIAN 12 NO. 608 36
Frontotemporal dementia Alzheimer s disease 37 CLINICIAN 12 NO. 608
CLINICIAN 12 NO. 608 38
39 CLINICIAN 12 NO. 608
Rascovsky, K., et al. : Sensitivity of revised diagnostic criteria for the behavioural variant of frontotemporal CLINICIAN 12 NO. 608 40
Brain, 134, 2456-2477 (2011) dementia. Zamboni, G., et al. : Apathy and disinhibition in frontotemporal dementia : Insights into their neural Neurology, 71, 736-742 (2008) correlates. Mendez, M. F., et al. : Stereotypical movements and frontotemporal dementia. Mov. Disord., 20, 742-745 (2005) Ikeda, M., et al. : Changes in appetite, food preference, and eating habits in frontotemporal dementia and Alzheimer s disease. J. Neurol. Neurosurg. Psychiatry, 371-376 (2002) 73, McMurtray, A. M., et al. : Variations in regional SPECT hypoperfusion and clinical features in frontotemporal Neurology, 66, 517-522 (2006) dementia. Ikeda, M. : Fronto-temporal dementia. Richie, C. W., et al. ed., Therapeutic strategies in dementia. Clinical Oxford, 287-299 (2007) Publishing, Ikeda, M., et al. : Efficacy of fluvoxamine as a treatment for behavioral symptoms in frontotemporal lobar degeneration patients. Dement. Geriatr. Cogn. Disord., 17, 117-121 (2004) 41 CLINICIAN 12 NO. 608
Behavioral and Psychological Symptoms of Dementia Mild Cognitive Impairment CLINICIAN 12 NO. 608 42
43 CLINICIAN 12 NO. 608
Kitwood Kitwood CLINICIAN 12 NO. 608 44
45 CLINICIAN 12 NO. 608
CLINICIAN 12 NO. 608 46
12, 191-199 (2009) symptoms of dementia. Int. J. Neuropsychopharmacol., the treatment of the behavioural and psychological (1997) Mizukami, K., et al. : A randomized cross-over study of a traditional Japanese medicine (kampo), yokukansan, in (2002) 1475-1483 Kitwood, T. : Dementia Reconsidered : The Person Comes First. Open University Press, Buckingham results from the cardiovascular health study. JAMA, 288, (2004) Lyketsos, C. G., et al. : Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment :, symptoms. Alzheimer Dis. Assoc. Disord., 18 (1), 17-21 associated with characteristic neuropsychiatric Hwang, T. J., et al. : Mild cognitive impairment is 47 CLINICIAN 12 NO. 608
hallucination illusion misidentification delusion CLINICIAN 12 NO. 608 48
Bassiony 49 CLINICIAN 12 NO. 608
Ikeda CLINICIAN 12 NO. 608 50
frontotemporal lobar degeneration Engelborghs......... Capgras....... TV........... 51 CLINICIAN 12 NO. 608
AchEIs CLINICIAN 12 NO. 608 52
AchEIs Shigenobu AchEIs 53 CLINICIAN 12 NO. 608
Rubin, E. H., et al. : The nature of psychotic symptoms in senile dementia of the Alzheimer type. J. Geriatr. Psychiatry Neurol., 1, 16-20 (1988) Hirono, N., et al. : Distinctive neurobehavioral features among neurodegenerative dementias. J. Neuropsy- chiatry Clin. Neurosci., 11, 498-503 (1999) Stavitsky, K., et al. : The progression of cognition, psychiatric symptoms, and functional abilities in dementia with Lewy bodies and Alzheimer disease. Arch. Neurol., 63, 1450-1456 (2006) Aalten, P., et al. : Neuropsychiatric syndromes in dementia. Results from the European Alzheimer disease consortium : part 1. Dement. Geriatr. Cogn. Disord., 24, 457-463 (2007) Engelborghs, S., et al. : Neuropsychiatric symptoms of dementia : cross-sectional analysis from a prospective, longitudinal Belgian study. Int. J. Geriatr. Psychiatry, 20, 1028-1037 (2005) Bassiony, M. M., Lyketsos, C. G. : Delusion and hallucination in Alzheimer s disease : review of the brain decade. Psychosomatics, 44, 388-401 (2003) Nagahama, Y., et al. : Classification of psychotic symptoms in dementia with Lewy bodies. Am. J. Geriatr. Psychiatry, 15, 961-967 (2007) CLINICIAN 12 NO. 608 54
risperidone therapy for delusions of theft in Alzheimer Shigenobu, K., et al. : A structured, open trial of 66, 935-937 (2006) Neurology, of Neurology (2012), http : //onlinelibrary. wiley. com/ 23557/abstract Mori, T., et al. : Correlation of visual hallucinations with doi/10.1002/ana. occipital rcbf changes by donepezil in DLB. J. Geriatr. Psychiatry Neurol., 19, 220-225 (2006) Mori, E., et al. : Donepezil for dementia with Lewy clinic. bodies : A randomized, placebo-controlled trial. Annals Neurosurg. Psychiatry, 76, 1337-1341 (2005) Nagahama, Y., et al. : The Cambridge Behavioral Neurol. Inventory : validation and application in a memory Neurosurg. Psychiatry, 75, 146-148 (2004) Fuh, J. L., et al. : Neuropsychiatric profiles in patients Neurol. with Alzheimer s disease and vascular dementia. J. elderly : findings from the first Nakayama study. J. behavioral disturbances in community dwelling Ikeda, M., et al. : Dementia-associated mental and Am. J. Geriatr. Psychiatry, 11, 256-257 (2003) Nagahama, Y., et al. : Neural correlates of psychotic disease. symptoms in dementia with Lewy bodies. Brain, 133, 568-579 (2010) 55 CLINICIAN 12 NO. 608
agitation Cohen- CLINICIAN 12 NO. 608 56
Mansfield Agitation Inventory Neuropsychiatric Inventory agitation agitation Behavioral and Psychological Symptoms of Dementia............ 57 CLINICIAN 12 NO. 608
CLINICIAN 12 NO. 608 58
Howard, R. J., et al. ; CALM-AD Trial Group : Donepezil for the treatment of agitation in Alzheimer s disease. N. Engl. J. Med., 357 (14), 1382-1392 (2007) Gauthier, S., et al. ; Donepezil MSAD Study Investigators Group : Efficacy of donepezil on behavioral symptoms in patients with moderate to severe Alzheimer s disease. Int. Psychogeriatr., 14, 389-404 (2002) 59 CLINICIAN 12 NO. 608
CLINICIAN 12 NO. 608 60
61 CLINICIAN 12 NO. 608
Swedish Alzheimer Treatment Study Instrumental ADL CLINICIAN 12 NO. 608 62
DOMINO study 63 CLINICIAN 12 NO. 608
CLINICIAN 12 NO. 608 64
Geldmacher, D. S., et al. : Donepezil is associated with delayed nursing home 65 CLINICIAN 12 NO. 608
placement in patients with Alzheimer s disease. J. Am. Geriatr. Soc., 51 (7), 937-944 (2003) http : //www8.cao.go.jp/ kourei/ishiki/h22/kiso/zentai/index.html Wattmo, C., et al. : Risk factors for nursing home placement in Alzheimer s disease : a longitudinal study of cognition, ADL, service utilization, and cholinesterase inhibitor treatment. Gerontologist, 51 (1), 17-27 (2011) Mohs, R. C., et al. : A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology, 57 (3), 481-488 (2001) Howard, R., et al. : Donepezil and memantine for moderate-to-severe Alzheimer s disease. N. Engl. J. Med., 366 (10), 893-903 (2012) Waldemar1, G., et al. : Effect of donepezil on emergence of apathy in mild to moderate Alzheimer s disease. Int. J. Geriatr. Psychiatry, 26, 150-157 (2011) CLINICIAN 12 NO. 608 66
Alzheimer s Disease As- 67 CLINICIAN 12 NO. 608
sessment Scale ADAS-cog. ADAS-cog. DT-Navi ADAS- Jcog. DT-Navi DT-Navi CLINICIAN 12 NO. 608 68
ADAS-Jcog. ADAS-Jcog. ADAS-Jcog. ADAS-Jcog. Behavioral Pathological 69 CLINICIAN 12 NO. 608
in Alzheimer s Disease Behave-AD ADAS-Jcog. Behave-AD CLINICIAN 12 NO. 608 70
ADAS-Jcog. Instrumental Activities of Daily Living ADAS-Jcog. ADAS-Jcog. 71 CLINICIAN 12 NO. 608
CLINICIAN 12 NO. 608 72
73 CLINICIAN 12 NO. 608 repetitive Transcranial Magnetic Stimulation Barker Hz Pascual-Leone
CLINICIAN 12 NO. 608 74 Hz Hz Hz Hz
75 CLINICIAN 12 NO. 608
CLINICIAN 12 NO. 608 76 George, M. S., Post, R. M. : Daily left prefrontal repetitive transcranial magnetic stimulation for acute treatment of medication-resistant depression. Am. J. Psychiatry, 168, 356-364 (2011) Tani, N., Saitoh, Y., et al. : Motor cortex stimulation for levodopa-resistant akinesia : case report. Mov. Disord., 22, 1645-1649 (2007) Leung, A., et al. : rtms for suppressing neuropathic pain: a meta-analysis. J. Pain, 10, 1205-1216 (2009) Khedr, E. M., et al. : Therapeutic trial of repetitive transcranial magnetic stimulation after acute ischemic stroke. Neurology, 65, 466-468 (2005) Rossi, S., et al. : Safety, ethical considerations, and application guidelines for the use of transcranial magnetic stimulation in clinical practice and research. Clin. Neurophysiol., 120, 2008-2039 (2009)
EuroQol 77 CLINICIAN 12 NO. 608
CLINICIAN 12 NO. 608 78
79 CLINICIAN 12 NO. 608
0.094 CLINICIAN 12 NO. 608 80
81 CLINICIAN 12 NO. 608
Tanaka, T., et al. : Post-marketing survey of donepezil hydrochloride in Japanese patients with Alzheimer s disease with behavioral and psychological symptoms of dementia (BPSD). Psychogeriatrics, 8 (3), 114-123 (2008) EuroQol EQ-5D, VAS National Collaborating Centre for Mental Health : NICE clinical guideline 42 ; Dementia (2006) CLINICIAN 12 NO. 608 82
Mild Cognitive Impairment Petersen Alzheimer s disease Alzhei- 83 CLINICIAN 12 NO. 608
mer s Disease Neuroimaging Initiative Doody ADAS-Cog. Salloway ADAS-Cog. CLINICIAN 12 NO. 608 84
Petersen Winblad NYU Paragraph Recall Test InDDEx 85 CLINICIAN 12 NO. 608
α α allosteric potentiating ligand CLINICIAN 12 NO. 608 86
Petersen, R. C., et al. : Apolipoprotein E status as a predictor of the development of Alzheimer s disease in memory-impaired individuals. JAMA, 273 (16), 1274-1278 (1995) Weiner, M. W., et al. : The Alzheimer s disease neuroimaging initiative : progress report and future plans. Alzheimers Dement., 6 (3), 202-211, e7 (2010) 87 CLINICIAN 12 NO. 608
glutamate neurotoxicity in rat cortical neurons. J. (2011) 58-66 Takada, Y., et al. : Nicotinic acetylcholine receptormediated neuroprotection by donepezil against Disease Neuroimaging Initiative. Arch. Neurol., 68 (1), (2007) 501-512 Schneider, L. S., et al. : Treatment with cholinesterase inhibitors and memantine of patients in the Alzheimer s impairment : the InDDEx study. Lancet Neurol., 6 (6), (22), 2024-2035 (2008) 70 Feldman, H. H., et al. : Effect of rivastigmine on delay to diagnosis of Alzheimer s disease from mild cognitive (23), 2379-2388 (2005) 352 Winblad, B., et al. : Safety and efficacy of galantamine in subjects with mild cognitive impairment. Neurology, trial. Neurology, 63 (4), 651-657 (2004) controlled Petersen, R. C., et al. : Vitamin E and donepezil for the treatment of mild cognitive impairment. N. Engl. J. Med., 72 (18), 1555-1561 (2009) Neurology, Salloway, S., et al. : Efficacy of donepezil in mild cognitive impairment : a randomized placebo- MCI : a 48-week randomized, placebo-controlled trial. Doody, R. S., et al. : Donepezil treatment of patients with Exp. Ther., 306 (2), 772-777 (2003) Kihara, T., et al. : Galantamine modulates nicotinic Pharmacol. receptor and blocks Abeta-enhanced glutamate toxicity. Biochem. Biophys. Res. Commun., 325 (3), 976-982 Zhou, X., et al. : Acteylcholinesterase inhibitor (2004) rivastigmine enhances cellular defenses in neuronal and macrophage-like cell lines. Transl. Res., 153 (3), 132-141 (2009) CLINICIAN 12 NO. 608 88
89 CLINICIAN 12 NO. 608
treatable dementia behavioral and psychological symptoms of dementia Mini-Mental State Examination CLINICIAN 12 NO. 608 90
p=0.005 p=0.019 p=0.004 p =0.001 91 CLINICIAN 12 NO. 608
CLINICIAN 12 NO. 608 92
symptomatic drug disease modifying drug 93 CLINICIAN 12 NO. 608
CLINICIAN 12 NO. 608 94
95 CLINICIAN 12 NO. 608
CLINICIAN 12 NO. 608 96
97 CLINICIAN 12 NO. 608
CLINICIAN 12 NO. 608 98
99 CLINICIAN 12 NO. 608
CLINICIAN 12 NO. 608 100
behavioral and psychological symptoms of dementia 101 CLINICIAN 12 NO. 608
ACh ACh BCh ACh CLINICIAN 12 NO. 608 102
ACh AChE mini-mental state examination Hasegawa s dementia scale-revised 103 CLINICIAN 12 NO. 608
CLINICIAN 12 NO. 608 104
Abe, K., et al. : Ascorbate induced lipid peroxidation results in loss of receptor binding in Tris, but not phosphate, buffer. Biochem. Int., 11, 341-348 (1985) 105 CLINICIAN 12 NO. 608
CLINICIAN 12 NO. 608 106
107 CLINICIAN 12 NO. 608
BPSD CLINICIAN 12 NO. 608 108
109 CLINICIAN 12 NO. 608
http : //www.fukushihoken.metro.tokyo.jp/ zaishien/ninchishou_navi/kisochishiki/ninchishou/data/ index.html CLINICIAN 12 NO. 608 110
111 CLINICIAN 12 NO. 608
Clinical Dementia Rating CLINICIAN 12 NO. 608 112
http : //www.med. nagoya-u.ac. jp/ pharmacy/ 03/ textbook/ textbook. pdf Mini- Mental State Examination 113 CLINICIAN 12 NO. 608
CLINICIAN 12 NO. 608 114
Functional Assessment Staging 115 CLINICIAN 12 NO. 608
Umegaki, H., et al. : Discontinuation of donepezil for the treatment of Alzheimer s disease in geriatric practice. Int. Psychogeriatr., 20, 800-806 (2008) CLINICIAN 12 NO. 608 116
117 CLINICIAN 12 NO. 608
CLINICIAN 12 NO. 608 118
119 CLINICIAN 12 NO. 608
OD-mate CLINICIAN 12 NO. 608 120
121 CLINICIAN 12 NO. 608
A.S.P.E.N. Board of Directors and The Clinical Guidelines Task Force : Guidelines for the use of parenteral and enteral nutrition in adult and pediatric patients. JPEN, 26 (Suppl), 8SA (2002) CLINICIAN 12 NO. 608 122
Therapeutic Research 123 CLINICIAN 12 NO. 608
CLINICIAN 12 NO. 608 124
125 CLINICIAN 12 NO. 608
CLINICIAN 12 NO. 608 126
127 CLINICIAN 12 NO. 608
CLINICIAN 12 NO. 608 128
129 CLINICIAN 12 NO. 608
CLINICIAN 12 NO. 608 130
131 CLINICIAN 12 NO. 608
CLINICIAN 12 NO. 608 134